Skip to main content

Basal Cell Carcinoma clinical trials at UCSF

1 research study open to eligible people

Basal Cell Carcinoma is a type of skin cancer. UCSF has a clinical trial for a treatment called RP1. The trial will test how well RP1 works and how safe it is for people with advanced cutaneous malignancies. There is also another trial in progress, but it is not accepting new participants.

Showing trials for
  • RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies

    open to eligible people ages 18 years and up

    This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients. Patients will participate up to approximately 3 years including a 28-day screening period, up to approximately 1 year treatment period, and a 2-year follow-up period.

    San Francisco, California and other locations

Our lead scientists for Basal Cell Carcinoma research studies include .

Last updated: